Consun Pharmaceutical Group Limited (HKEX: 01681) is a modern pharmaceutical group headquartered in Guangzhou, with a strong heritage in traditional Chinese medicine and complementary chemical medicines, strategically focused on nephrology.
Positioning
Consun aims to be the partner-of-choice in China's nephrology market while growing across gynecology & pediatrics, imaging contrast agents, orthopedics, dermatology and other therapeutic areas. The Group operates manufacturing and commercial entities including Yulin Pharmaceutical and Inner Mongolia facilities, with nationwide hospital coverage.
Core Businesses
Nephrology
Flagship products such as Uremic Clearance Granules supported by clinical evidence and academic programs, maintaining market-leading position.
Multi-therapy Portfolio
Imaging agents, iron supplementation, topical orthopedics, dermatology, hepatobiliary and digestive products across 8 therapeutic areas.
R&D Innovation
Innovative assets and high-quality generics with global partnering and industry-academia collaboration.
Vision
To serve patients with quality medicines and drive industry progress through innovation, becoming a respected modern pharmaceutical enterprise.